Blocking of the B7-CD28 Pathway Increases the Capacity of FasL+ (CD95L+) Dendritic Cells to Kill Alloactivated T Cells
Dendritic cells (DC) are antigen presenting cells of hemopoietic origin, uniquely well-equipped to activate naive T cells.1 Evidence also exists however, for DC tolerogenicity.2 During primary activation, mature T cells change from an activation-induced cell death (AICD) -resistant to an AICD-sensitive phenotype.3 The complete molecular basis for this transition remains to be determined, but CD95 (Fas/Apo-1) and CD95L (Fas ligand; FasL) appear to play an important role in the homeostatic regulation of T cell responses.4 It seems that CD95L can mediate opposite effects (T cell activation or apoptosis) depending on the state of activation of the responding T cells. Previously, we have shown that mouse bone marrow (BM)-derived DC progenitors deficient in expression of cell surface costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are capable of inducing alloantigen-specific T cell hyporesponsiveness5 and prolonging allograft survival.6 Others have shown recently that a major subpopulation of freshly-isolated mouse lymphoid tissue DC is FasL+, and can induce apoptosis in allogeneic T cells.7 In the course of studies on DC propagated in vitro from mouse BM, we observed that these cells expressed Fas L. Our aim was to determine whether these cells could induce T cell apoptosis and whether costimulatory molecule expression could affect this activity.
KeywordsDendritic Cell Mouse Bone Marrow FasL Expression CD28 Costimulation Mixed Leukocyte Reaction
Unable to display preview. Download preview PDF.
- 6.Fu, F., Y. Li, S. Qian, L. Lu, F. Chambers, T.E. Starzl. J.J. Fung, and A.W. Thomson. 1996. Costimulatory molecule-deficient dendritic cell progenitors (MHC class ll’. B7-`’’, B7–2-) prolong cardiac allograft survival in non-immunosuppressed recipients. Transplantation 62: 659–665.PubMedCrossRefGoogle Scholar
- 8.Lu, L., W.A. Rudert, S. Qian, D. McCaslin, F. Fu, A.S. Rao, M. Trucco, J.J. Fung, T.E. Starzl, and A.W. Thomson. 1995. Growth of donor-derived dendritic cells from the bone marrow of liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J.Exp.Med. 182: 379–387.PubMedCrossRefGoogle Scholar
- 9.Lu, L., C.A. Bonham, F.G. Chambers, S.C. Watkins, R.A. Hoffman, R.L. Simmons, and A.W. Thomson. 1996. Induction of nitric oxide synthase in mouse dendritic cells by interferon y, endotoxin and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J. Immunol. In press.Google Scholar
- 10.Lu, L., J. Woo, A.S. Rao, Y. Li, S.C. Watkins, S. Qian, T.E. Starzl, A.J. Demetris, and A.W. Thomson. 1994. Propagation of dendritic cell progenitors from normal mouse liver using GM-CSF and their maturational development in the presence of type-1 collagen. J Exp. Med. 179: 1823–1834.PubMedCrossRefGoogle Scholar
- 13.Vremec, D., M. Zorbas, R. Scollay, D.J. Saunders, C.F. Ardavin, L. Wu, and K. Shortman. 1992. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J. Exp. Med. 176: 47–58.PubMedCrossRefGoogle Scholar
- 14.Wu, M.X., Z. Ao, M. Hegen, C. Morimoto, and S.F. Schlossman. 1996. Requirement of Fas (CD95), CD45, and CD 11 a/CD 18 in monocyte-dependent apoptosis of human T cells. J. Monona 157: 707–713.Google Scholar
- 17.Tian, L., R.J. Noelle, and D.A. Lawrence. 1995. Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-I. Eur. J. Immunol. 25: 306–309.Google Scholar
- 19.Nagata, S. 1994. Fas and Fas ligand: a death factor and its receptor. Adv. Immunol. 57: 129144.Google Scholar
- 20.Alderson, M.R., T.W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K.A. Schooley, R.G. Goodwin, C.A. Smith, F. Ramsdell, and D.H. Lynch. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181: 71–77.Google Scholar